Stingray Therapeutics Inc.
Houston, TX
- UEI
- XNADTMZYJMP5
- CAGE
- 826P1
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2450 Holcombe Blvd, Houston, TX 77021, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of a potent and selective oral ENPP1 inhibitor for oncology | National Cancer Institute (NIH) | $4,617,205 |
Quick answers
Is Stingray Therapeutics Inc. registered in SAM.gov?
Yes. Stingray Therapeutics Inc.'s SAM.gov registration is active through June 13, 2027.
What is Stingray Therapeutics Inc.'s most recent federal award?
Stingray Therapeutics Inc.'s most recent federal grant award is Development of a potent and selective oral ENPP1 inhibitor for oncology (R44CA278144), from National Cancer Institute (NIH), on September 15, 2022.
On GovTribe
See Stingray Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors